Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.21
AMRI's Cash to Debt is ranked lower than
93% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. AMRI: 0.21 )
Ranked among companies with meaningful Cash to Debt only.
AMRI' s 10-Year Cash to Debt Range
Min: 0.14  Med: 5.25 Max: No Debt
Current: 0.21
Equity to Asset 0.41
AMRI's Equity to Asset is ranked lower than
77% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AMRI: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
AMRI' s 10-Year Equity to Asset Range
Min: 0.41  Med: 0.82 Max: 0.96
Current: 0.41
0.41
0.96
Interest Coverage 0.52
AMRI's Interest Coverage is ranked lower than
99% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AMRI: 0.52 )
Ranked among companies with meaningful Interest Coverage only.
AMRI' s 10-Year Interest Coverage Range
Min: 0.52  Med: 22.78 Max: 1157.93
Current: 0.52
0.52
1157.93
F-Score: 2
Z-Score: 2.20
M-Score: -2.18
WACC vs ROIC
9.00%
56.28%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 0.18
AMRI's Operating margin (%) is ranked higher than
68% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -71.95 vs. AMRI: 0.18 )
Ranked among companies with meaningful Operating margin (%) only.
AMRI' s 10-Year Operating margin (%) Range
Min: -36.35  Med: 3.64 Max: 46.92
Current: 0.18
-36.35
46.92
Net-margin (%) -3.25
AMRI's Net-margin (%) is ranked higher than
66% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -68.66 vs. AMRI: -3.25 )
Ranked among companies with meaningful Net-margin (%) only.
AMRI' s 10-Year Net-margin (%) Range
Min: -31.74  Med: 4.77 Max: 77.21
Current: -3.25
-31.74
77.21
ROE (%) -4.23
AMRI's ROE (%) is ranked higher than
69% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. AMRI: -4.23 )
Ranked among companies with meaningful ROE (%) only.
AMRI' s 10-Year ROE (%) Range
Min: -22.52  Med: 4.01 Max: 29.93
Current: -4.23
-22.52
29.93
ROA (%) -1.90
AMRI's ROA (%) is ranked higher than
72% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. AMRI: -1.90 )
Ranked among companies with meaningful ROA (%) only.
AMRI' s 10-Year ROA (%) Range
Min: -17.99  Med: 2.83 Max: 23.57
Current: -1.9
-17.99
23.57
ROC (Joel Greenblatt) (%) 0.74
AMRI's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. AMRI: 0.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AMRI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -35.54  Med: 9.22 Max: 174.12
Current: 0.74
-35.54
174.12
Revenue Growth (3Y)(%) 8.20
AMRI's Revenue Growth (3Y)(%) is ranked higher than
61% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. AMRI: 8.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AMRI' s 10-Year Revenue Growth (3Y)(%) Range
Min: -1.5  Med: 7.75 Max: 78.2
Current: 8.2
-1.5
78.2
EPS Growth (3Y)(%) -54.80
AMRI's EPS Growth (3Y)(%) is ranked lower than
95% of the 420 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. AMRI: -54.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AMRI' s 10-Year EPS Growth (3Y)(%) Range
Min: -58.1  Med: -8.20 Max: 37.3
Current: -54.8
-58.1
37.3
» AMRI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

AMRI Guru Trades in Q3 2014

Paul Tudor Jones 16,255 sh (New)
Murray Stahl 56,000 sh (unchged)
Joel Greenblatt Sold Out
Chuck Royce 1,142,670 sh (-13.15%)
Jim Simons 209,242 sh (-63.91%)
» More
Q4 2014

AMRI Guru Trades in Q4 2014

Paul Tudor Jones 24,200 sh (+48.88%)
Chuck Royce 1,236,016 sh (+8.17%)
Murray Stahl 56,000 sh (unchged)
Jim Simons 126,142 sh (-39.71%)
» More
Q1 2015

AMRI Guru Trades in Q1 2015

Steven Cohen 233,100 sh (New)
Chuck Royce 1,291,216 sh (+4.47%)
Murray Stahl 56,000 sh (unchged)
Paul Tudor Jones 14,900 sh (-38.43%)
Jim Simons 62,242 sh (-50.66%)
» More
Q2 2015

AMRI Guru Trades in Q2 2015

Murray Stahl 56,000 sh (unchged)
Paul Tudor Jones Sold Out
Chuck Royce 1,219,316 sh (-5.57%)
Steven Cohen 184,900 sh (-20.68%)
Jim Simons 27,324 sh (-56.10%)
» More
» Details

Insider Trades

Latest Guru Trades with AMRI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 25.25
AMRI's Forward P/E is ranked lower than
55% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 22.73 vs. AMRI: 25.25 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.64
AMRI's P/B is ranked higher than
69% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. AMRI: 2.64 )
Ranked among companies with meaningful P/B only.
AMRI' s 10-Year P/B Range
Min: 0.28  Med: 1.09 Max: 3.08
Current: 2.64
0.28
3.08
P/S 1.98
AMRI's P/S is ranked higher than
87% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.19 vs. AMRI: 1.98 )
Ranked among companies with meaningful P/S only.
AMRI' s 10-Year P/S Range
Min: 0.31  Med: 1.70 Max: 2.93
Current: 1.98
0.31
2.93
POCF 37.64
AMRI's POCF is ranked lower than
55% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. AMRI: 37.64 )
Ranked among companies with meaningful POCF only.
AMRI' s 10-Year POCF Range
Min: 4.9  Med: 12.53 Max: 283.33
Current: 37.64
4.9
283.33
EV-to-EBIT 452.34
AMRI's EV-to-EBIT is ranked lower than
96% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 27.86 vs. AMRI: 452.34 )
Ranked among companies with meaningful EV-to-EBIT only.
AMRI' s 10-Year EV-to-EBIT Range
Min: -1628.6  Med: 12.70 Max: 1522.2
Current: 452.34
-1628.6
1522.2
Current Ratio 3.41
AMRI's Current Ratio is ranked lower than
57% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. AMRI: 3.41 )
Ranked among companies with meaningful Current Ratio only.
AMRI' s 10-Year Current Ratio Range
Min: 2.45  Med: 5.60 Max: 17.83
Current: 3.41
2.45
17.83
Quick Ratio 2.41
AMRI's Quick Ratio is ranked lower than
65% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. AMRI: 2.41 )
Ranked among companies with meaningful Quick Ratio only.
AMRI' s 10-Year Quick Ratio Range
Min: 1.84  Med: 4.88 Max: 17.25
Current: 2.41
1.84
17.25
Days Inventory 78.63
AMRI's Days Inventory is ranked higher than
66% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 120.98 vs. AMRI: 78.63 )
Ranked among companies with meaningful Days Inventory only.
AMRI' s 10-Year Days Inventory Range
Min: 21.14  Med: 63.97 Max: 125.59
Current: 78.63
21.14
125.59
Days Sales Outstanding 90.06
AMRI's Days Sales Outstanding is ranked lower than
66% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. AMRI: 90.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMRI' s 10-Year Days Sales Outstanding Range
Min: 30.71  Med: 53.59 Max: 169.08
Current: 90.06
30.71
169.08

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.75
AMRI's Price/Tangible Book is ranked lower than
52% of the 693 Companies
in the Global Biotechnology industry.

( Industry Median: 5.31 vs. AMRI: 5.75 )
Ranked among companies with meaningful Price/Tangible Book only.
AMRI' s 10-Year Price/Tangible Book Range
Min: 0.39  Med: 1.63 Max: 16.72
Current: 5.75
0.39
16.72
Price/Projected FCF 3.27
AMRI's Price/Projected FCF is ranked higher than
58% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. AMRI: 3.27 )
Ranked among companies with meaningful Price/Projected FCF only.
AMRI' s 10-Year Price/Projected FCF Range
Min: 0.4  Med: 0.84 Max: 3.31
Current: 3.27
0.4
3.31
Price/Median PS Value 1.19
AMRI's Price/Median PS Value is ranked lower than
57% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: 1.08 vs. AMRI: 1.19 )
Ranked among companies with meaningful Price/Median PS Value only.
AMRI' s 10-Year Price/Median PS Value Range
Min: 0.23  Med: 1.22 Max: 24.97
Current: 1.19
0.23
24.97
Price/Peter Lynch Fair Value 7.77
AMRI's Price/Peter Lynch Fair Value is ranked lower than
2079% of the 52 Companies
in the Global Biotechnology industry.

( Industry Median: 1.85 vs. AMRI: 7.77 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
AMRI' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.74  Med: 2.08 Max: 80.81
Current: 7.77
0.74
80.81
Earnings Yield (Greenblatt) (%) 0.21
AMRI's Earnings Yield (Greenblatt) (%) is ranked higher than
73% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. AMRI: 0.21 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AMRI' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.1  Med: 3.90 Max: 15.1
Current: 0.21
0.1
15.1
Forward Rate of Return (Yacktman) (%) 16.23
AMRI's Forward Rate of Return (Yacktman) (%) is ranked higher than
57% of the 100 Companies
in the Global Biotechnology industry.

( Industry Median: 13.39 vs. AMRI: 16.23 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AMRI' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -17.6  Med: 0.20 Max: 23.6
Current: 16.23
-17.6
23.6

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 366 398
EPS($) 0.63 0.79
EPS without NRI($) 0.63 0.79

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AYM.Germany,
Albany Molecular Research Inc is a Delaware corporation incorporated on June 20, 1991. It is a contract research and manufacturing organization providing customers integrated drug discovery, development and manufacturing services. The Company provides services and technologies that support the discovery and development of pharmaceutical products and the manufacturing of Active Pharmaceutical Ingredients (API) and drug product for existing and experimental new drugs, as well as research, development and manufacturing for the agrochemical and other industries. With locations in the United States, Europe, and Asia, it maintains geographic proximity and flexible cost models. The Company has organized its activities into two distinct segments: Large Scale Manufacturing (LSM) and Discovery, Drug Development and Small-Scale Manufacturing (DDS). Its LSM activities include pilot- to commercial-scale production of active pharmaceutical ingredients and intermediates, sterile syringe and vial filling, and high potency and controlled substance manufacturing. Its remaining activities, including drug lead discovery, in vitro biology and DMPK, lead optimization, drug development, and small-scale commercial manufacturing, represent its DDS business segment. Its Drug Discovery Services includes assay development and design, screening, natural product services, custom synthesis and library synthesis, medicinal chemistry, bioanalytical services, among others. Its customers include pharmaceutical companies and biotechnology companies, as well as government research entities and non-profit organizations, which are a growing segment of its customer base. It also sells to a more limited extent, to companies who are in the businesses of agriculture, fine chemicals, contract chemical manufacturing, medical devices, and flavoring and cosmetics. The Company competes with contract research companies, contract drug manufacturing companies, research and academic institutions and with the internal research departments of biotechnology companies. The manufacture, transportation and storage of its products are subject to certain international, Federal, state and local laws and regulations.
» More Articles for AMRI

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: TSON, PRTS, FXCM, AMRI, MN Dec 05 2011 
View on AMRI Jun 27 2010 
AMRI Announces Second Quarter 2009 Results Aug 04 2009 
AMRI Announces Fourth Quarter 2008 Results Feb 09 2009 
AMRI Names Senior Director, Analytical and Quality Services Jan 12 2009 

More From Other Websites
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Entry into a Material Definitive Agreement Aug 19 2015
ALBANY MOLECULAR RESEARCH INC Financials Aug 18 2015
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Regulation FD Disclosure Aug 12 2015
10-Q for Albany Molecular Research, Inc. Aug 09 2015
ALBANY MOLECULAR RESEARCH INC Files SEC form 10-Q, Quarterly Report Aug 07 2015
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Aug 05 2015
Edited Transcript of AMRI earnings conference call or presentation 4-Aug-15 12:30pm GMT Aug 04 2015
Albany Molecular Research posts 2Q profit Aug 04 2015
Albany Molecular Research posts 2Q profit Aug 04 2015
Albany Molecular Research Inc Earnings Call scheduled for 8:30 am ET today Aug 04 2015
AMRI Announces Second Quarter 2015 Results Aug 04 2015
Q2 2015 Albany Molecular Research Inc Earnings Release - Before Market Open Aug 04 2015
PerkinElmer Beats Q2 Earnings and Revenues; Guides Up - Analyst Blog Jul 31 2015
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jul 29 2015
AMRI to Announce Second Quarter 2015 Results Jul 21 2015
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 16 2015
AMRI Acquires Gadea Pharmaceutical Group Jul 16 2015
AMRI and IBM projects in Buffalo represent transitioning businesses Jul 09 2015
Edited Transcript of AMRI presentation 1-Jun-15 7:30pm GMT Jun 25 2015
AMRI continues to build Buffalo partnerships Jun 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK